VeriTeQ to sell long-approved microchip for wireless tracking of breast implants

VeriTeQ has announced plans to market VeriChip, its passive radiofrequency identification (RFID) microchip, for identifying and tracing the whereabouts of breast implants.

In announcing the offering, the Delray Beach, Fla.-based manufacturer said it believes the 8-millimeter microchip can also be used safely and effectively in artificial joint replacements.

VeriTeQ said the FDA cleared the VeriChip for sale in 2004. The company did not explain the eight-year lag between approval and availability.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup